Speakers from left to right:
Dr Phillip Castle,
Dr. Scott LaMontagne
and Dr Lauri Markowitz


Dr Philip Castle

On January 1, 2011, Dr Philip Castle became the Executive Director of American Society for Clinical Pathology (ASCP) Institute. Previously, he was a Senior, Tenured Investigator (2010-2011) and Tenure-Track Investigator (2003-10) in the Division of Canver Epidemiology and Genetics (DCEG) at the U.S National Cancer Insitute (NCI).

He reveived hi Ph.D. in Biophysics in 1995 and M.P.H. in Epidemiology in 2000 from the John Hopkins University. Dr. Castle did a post-doctoral fellowship at the NIH on the molecular biology of the zona pellucida from 1995-1999, and was a Cancer Prevention Fellow at NCI from 2000-2003.

Dr. Castle’s professional interests are (1) epidemiology of human papillomaviruses (HPV) and cervical/anogenital cancer; (2) science and translation of cancer prevention strategies; (3) evidence-based medicine; and (4) international health. At ASCP, Dr. Castle will be leading two programs, the Center for Health Services Research and for Global Outreach. Whiles at the NCI,he is the lead investigator on several epidemiologic studies, including the Mississippi Delta Project, The HPV Persistence and Progression Cohort at Kaiser Permanente Northern California, the Anal Cancer Screening Study, and the Low-Cost Molecular Cervical Cancer Screening Study in China. Dr. Castle has published over 200 papers on HPV and cervical cancer, including in such prestigious journals as the New England Journal of Medicine, Lancet Oncology, Journal of the National Cancer Institute, British Medical Journal, and Cancer Research. He currently serves on the editorial boards of the Journal of Infectious Diseases and Journal of Lower Genital Tract Disease. He has served an invited speaker or session chair in many forums, including for the American Association for Cancer Research, International Papillomavirus Society, and the European Inion on Genital Infection and Neoplasia (EUROGIN). He regulary participates in development of national and international guidelines for cervical prevention. He serves a consultant for several countires on the development of national cervical cancer prevention programs.

For his work in cervical cancer prevention, Dr. Castle has received (1) An EUROGIN Distinguished Service Award (2006); (2) a NIH Merit Award for introduction of HPV testing into low-resource settings in the U.S. (2007); (3) a Distinguished Scientific Achievement Award by American Society For Colposcopy and Cervical Pathology (2010), its highest honor; and (4) The Arthur S. Flemming Award for Exceptional Achievement in Federal Government Service for Applied Science, Engineering and Mathematics (2010).

Dr Castle's attendance at PCC2011 is proudly sponsored by the Cancer Council New South Wales.


Dr. Scott LaMontagne

Dr. Scott LaMontagne is currently the country research manager for the HPV vaccine demonstration projects at PATH (Program for Appropriate Technology in Health). He has over 15 years of experience in infectious disease surveillance, operations and implementation research, public health program implementation, monitoring and evaluation, and project management for government and non-governmental agencies at local, state, and national levels in developed and developing countries. He is a specialist in surveillance and epidemiology of human papillomavirus, Chlamydia trachomatis, tuberculosis, and sexually transmitted infections.

Previous to PATH, he was the lead scientist and member of the Executive Management team for the National Chlamydia Screening Program in England. His career has focused on bridging the gap between research and policy by focusing on evidence-based decision-making in program implementation. Dr. LaMontagne has a PhD from Middlesex University in London, England, a Master’s in Public Health in International Health from Yale University, and a Bachelor of Arts degree in Japanese studies from the University of Washington.


Dr Lauri Markowitz

Dr. Markowitz is the Team Lead for Epidemiology Research in the Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC). Since 2004, she has coordinated the HPV Vaccine Working Group of the Advisory Committee on Immunization Practices (ACIP). In this capacity, she spearheaded the development of recommendations for use of HPV vaccine in the US. Dr Markowitz has provided consultation related to HPV vaccine to a variety of national and international groups, and is a member of HPV Expert Advisory Group at the World Health Organization. Dr. Markowitz received her medical degree from Albert Einstein College of Medicine in New York and completed her residency training in Internal Medicine at the University of Pennsylvania. She joined CDC in 1983 as an EIS Officer in the National Center for Infectious Diseases. Since 1998, she has been in her current position in NCHHSTP, working on and supervising research related to sexually transmitted infections. Her work on HPV has included epidemiology studies and as well as policy issues. Dr. Markowitz has authored and/or co-authored over 100 research papers on infectious diseases and vaccine preventable diseases.


Local speakers still to be confirmed. Please stay tuned for details.